Greenbrook TMS Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Greenbrook TMS Inc. specializes in providing Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive treatment for Major Depressive Disorder and other mental health conditions. The company operates a network of treatment centers across the United States, delivering over 840,000 TMS treatments to more than 24,000 patients. Core services include TMS therapy sessions, Spravato® (esketamine) treatment programs, medication management, and talk therapy. Greenbrook also offers integrated mental health treatment services through its treatment centers, targeting patients with treatment-resistant depression and related disorders. The company was founded in 2011 and is headquartered in Toronto, Canada. In recent major developments, Greenbrook completed the acquisition of Success TMS, a large TMS therapy provider, in mid-2022, substantially expanding its footprint to 193 active TMS centers across multiple U.S. states including Florida, Pennsylvania, Illinois, New Jersey, Nevada, and Wisconsin. This acquisition broadened Greenbrook's market presence and diversified its geographic operations. Additionally, the company has been expanding its Spravato® offering, as well as medication management and talk therapy services. In 2024, Greenbrook was acquired by Neuronetics, creating a combined entity that integrates Neuronetics' NeuroStar TMS technology platform with Greenbrook's extensive clinical network. This strategic merger aims to enhance operational efficiencies, expand patient access, and drive growth across the U.S. mental health therapy market. Greenbrook operates primarily within the mental health and medical device sectors, focusing on therapeutic treatment delivery for depressive disorders. Its target customers are patients with Major Depressive Disorder and other mental health conditions who have not responded adequately to traditional antidepressants or psychotherapy. The company leverages partnerships and strategic alliances, such as its research collaboration to develop scalable psilocybin treatment delivery models. As a subsidiary of Neuronetics since December 2024, Greenbrook benefits from integrated technology platforms, centralized services, and enhanced revenue cycle management to strengthen its market position. Overall, Greenbrook TMS Inc. delivers specialized TMS and related mental health treatments through a growing network of centers, with recent expansions driven by acquisitions, service diversification, and its transformative acquisition by Neuronetics, positioning it as a leading provider in the U.S. mental health therapy space.
Company News
GREENBROOK TMS ANNOUNCES DELISTING FROM NASDAQ
Greenbrook Announces $1.2 Million Registered Direct Offering
Why Is Greenbrook TMS (GBNH) Stock Up 174% Today?
GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING
GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING
GREENBROOK APPOINTS PETER WILLETT AS CHIEF FINANCIAL OFFICER
GREENBROOK TMS ANNOUNCES DIRECTOR APPOINTMENT
GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING
GREENBROOK TMS RAISES US$5.3 MILLION IN DEBT FINANCING
GREENBROOK TMS RAISES US$4.0 MILLION IN DEBT FINANCING
GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING
Greenbrook TMS Announces Settlement of Ongoing Litigation
GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING
Greenbrook TMS Inc. (GBNH) Q3 2023 Earnings Call Transcript
GREENBROOK TMS REPORTS THIRD QUARTER OPERATIONAL AND FINANCIAL RESULTS
GREENBROOK TMS RAISES US$2.0 MILLION IN DEBT FINANCING
GREENBROOK TMS ANNOUNCES DIRECTOR APPOINTMENT
GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2023 FINANCIAL RESULTS
GREENBROOK APPOINTS INTERIM CHIEF FINANCIAL OFFICER
GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING